family with sequence similarity 163 member AGenealiases: C1orf76 · NDSP
Q-omics provides the consensus-scored FAM163A profile across patient tissues and cancer cell-line models. FAM163A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FAM163A is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FAM163A RNA expression shows 16,294 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where FAM163A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM163A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM163A survival associations across molecular data types. FAM163A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM163A RNA expression–survival associations across cancer types. High FAM163A expression shows unfavorable associations in UVM, KIRP, LIHC and MESO, but favorable associations in KIRC and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FAM163A RNA expression.
This table summarizes FAM163A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM163A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM163A shows lower tumor expression in THCA and COAD and higher tumor expression in KIRC, HNSC, LUAD and BRCA. The KIRC box plot shows higher FAM163A RNA expression in tumor versus normal tissue (log2 FC = +1.185, t-test p < 0.001).
This table shows molecular features associated with FAM163A in patient tissues and cancer cell lines. In patient samples, FAM163A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM163A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Myeloma.
